EGFR and non-small cell lung carcinoma: Given the high incidence and poor outcomes associated with KRASmut NSCLC, we further explored the interaction between alisertib and erlotinib in two KRASmut cell lines, A549 and H358 cells, both of which expressed appreciable levels of AURKA and EGFR, and both of which had significant single-agent response to these drugs (Fig. 2A and E).